Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis
Milk-derived extracellular vesicles (mEVs) have been proposed as a potential nanomedicine for intestinal disorders; however, their impact on intestinal barrier integrity in gut inflammation and associated metabolic diseases has not been explored yet. Here, mEVs derived from bovine and human breast milk exert similar protective effects on epithelial tight junction functionality in vitro, survive harsh gastrointestinal conditions ex vivo, and reach the colon in vivo. Oral administration of mEVs restores gut barrier integrity at multiple levels, including mucus, epithelial, and immune barriers, and prevents endotoxin translocation into the liver in chemical-induced experimental colitis and diet-induced nonalcoholic steatohepatitis (NASH), thereby alleviating gut disorders, their associated liver inflammation, and NASH. Oral administration of mEVs has potential in the treatment of gut inflammation and gut-liver axis-associated metabolic diseases via protection of intestinal barrier integrity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Science advances - 9(2023), 15 vom: 14. Apr., Seite eade5041 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tong, Lingjun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 14.04.2023 Date Revised 21.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1126/sciadv.ade5041 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355480050 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355480050 | ||
| 003 | DE-627 | ||
| 005 | 20231226064431.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1126/sciadv.ade5041 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355480050 | ||
| 035 | |a (NLM)37043568 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tong, Lingjun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Milk-derived extracellular vesicles protect intestinal barrier integrity in the gut-liver axis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.04.2023 | ||
| 500 | |a Date Revised 21.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Milk-derived extracellular vesicles (mEVs) have been proposed as a potential nanomedicine for intestinal disorders; however, their impact on intestinal barrier integrity in gut inflammation and associated metabolic diseases has not been explored yet. Here, mEVs derived from bovine and human breast milk exert similar protective effects on epithelial tight junction functionality in vitro, survive harsh gastrointestinal conditions ex vivo, and reach the colon in vivo. Oral administration of mEVs restores gut barrier integrity at multiple levels, including mucus, epithelial, and immune barriers, and prevents endotoxin translocation into the liver in chemical-induced experimental colitis and diet-induced nonalcoholic steatohepatitis (NASH), thereby alleviating gut disorders, their associated liver inflammation, and NASH. Oral administration of mEVs has potential in the treatment of gut inflammation and gut-liver axis-associated metabolic diseases via protection of intestinal barrier integrity | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Zhang, Sitong |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Qiqi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chenyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Hao, Haining |e verfasserin |4 aut | |
| 700 | 1 | |a Tan, Michelle Siying |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Xiaodong |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Charles Kang Liang |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Rong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Zhe |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Tongjie |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Pimin |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Cheng Han |e verfasserin |4 aut | |
| 700 | 1 | |a Muthiah, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Pastorin, Giorgia |e verfasserin |4 aut | |
| 700 | 1 | |a Wacker, Matthias Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Xiaoyuan |e verfasserin |4 aut | |
| 700 | 1 | |a Storm, Gert |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Cheun Neng |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Lanwei |e verfasserin |4 aut | |
| 700 | 1 | |a Yi, Huaxi |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiong-Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Science advances |d 2015 |g 9(2023), 15 vom: 14. Apr., Seite eade5041 |w (DE-627)NLM247717614 |x 2375-2548 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:15 |g day:14 |g month:04 |g pages:eade5041 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1126/sciadv.ade5041 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 15 |b 14 |c 04 |h eade5041 | ||